

Resource Summary Report

Generated by [RRID](#) on Aug 26, 2026

pCVL SFFV d14GFP EF1s HA.NLS.Sce(opt)

RRID:Addgene_31476

Type: Plasmid

Proper Citation

RRID:Addgene_31476

Plasmid Information

URL: <http://www.addgene.org/31476>

Proper Citation: RRID:Addgene_31476

Insert Name: SFFV d14 GFP donor EF1s I-SceI

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:21743461](#)

Vector Backbone Description: Backbone Size:5092; Vector Backbone:pCVL; Vector Types:Lentiviral; Bacterial Resistance:Ampicillin

Plasmid Name: pCVL SFFV d14GFP EF1s HA.NLS.Sce(opt)

Relevant Mutation: GFP has 14 amino acids deleted from c terminus

Record Creation Time: 20220422T222136+0000

Record Last Update: 20260815T081335+0000

Ratings and Alerts

No rating or validation information has been found for pCVL SFFV d14GFP EF1s HA.NLS.Sce(opt).

No alerts have been found for pCVL SFFV d14GFP EF1s HA.NLS.Sce(opt).

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Sottnik JL, et al. (2026) Altered MDC1 Interactions and Dysfunctional DNA Repair in Lobular Breast Cancer Confers Sensitivity to PARP Inhibition. *Cancer research*, 86(7), 1605.

Li P, et al. (2025) OFD1 inhibition induces BRCAness to create a therapeutic vulnerability to PARP inhibition in pancreatic cancer. *Nature communications*, 16(1), 7209.

Mei W, et al. (2025) A commonly inherited human PCSK9 germline variant drives breast cancer metastasis via LRP1 receptor. *Cell*, 188(2), 371.

Sottnik JL, et al. (2024) Co-regulator activity of Mediator of DNA Damage Checkpoint 1 (MDC1) is associated with DNA repair dysfunction and PARP inhibitor sensitivity in lobular carcinoma of the breast. *bioRxiv : the preprint server for biology*.

Brambati A, et al. (2023) RHINO restricts MMEJ activity to mitosis. *bioRxiv : the preprint server for biology*.

Folly-Kossi H, et al. (2023) DNA2 Nuclease Inhibition Confers Synthetic Lethality in Cancers with Mutant p53 and Synergizes with PARP Inhibitors. *Cancer research communications*, 3(10), 2096.

Mowat C, et al. (2021) Anti-tumor immunity in mismatch repair-deficient colorectal cancers requires type I IFN-driven CCL5 and CXCL10. *The Journal of experimental medicine*, 218(9).

Mehibel M, et al. (2021) Eliminating hypoxic tumor cells improves response to PARP inhibitors in homologous recombination-deficient cancer models. *The Journal of clinical investigation*, 131(11).

Chien JC, et al. (2021) Multiplexed bioluminescence-mediated tracking of DNA double-strand break repairs in vitro and in vivo. *Nature protocols*, 16(8), 3933.

Chien JC, et al. (2020) A multiplexed bioluminescent reporter for sensitive and non-invasive tracking of DNA double strand break repair dynamics in vitro and in vivo. *Nucleic acids research*, 48(17), e100.

Ohba S, et al. (2020) Phosphoglycerate Mutase 1 Activates DNA Damage Repair via Regulation of WIP1 Activity. *Cell reports*, 31(2), 107518.

Chroma K, et al. (2017) Tumors overexpressing RNF168 show altered DNA repair and responses to genotoxic treatments, genomic instability and resistance to proteotoxic stress. *Oncogene*, 36(17), 2405.

Rasmussen RD, et al. (2016) Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma. *Molecular oncology*, 10(5), 751.

Mateos-Gomez PA, et al. (2015) Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination. *Nature*, 518(7538), 254.